ESOG Hosts Strategic Meeting to Introduce Heat-Stable Carbetocin (HSC) into Ethiopia’s Maternal Health Program
On October 29, 2025, the Ethiopian Society of Obstetricians and Gynecologists (ESOG) held a pivotal consultation at its project bureau, bringing together key stakeholders—including representatives from Ferring Pharmaceuticals and the Maternity Foundation—to discuss the introduction of HSC into Ethiopia’s health system for postpartum hemorrhage (PPH) prevention.
The meeting highlighted Ethiopia’s urgent need for affordable, effective, and easy-to-administer solutions to reduce maternal mortality caused by PPH, which remains the leading cause of maternal death worldwide, especially in low-resource settings including Ethiopia. The participants emphasized HSC’s advantages over other uterotonics, including its stability at ambient temperatures, single-dose administration, and high efficacy. These features align perfectly with Ethiopia’s goals to improve maternal health outcomes by overcoming cold-chain challenges and expanding access to essential medicines.
This strategic dialogue marks a significant step toward integrating heat-stable Carbetocin into Ethiopia’s maternal health initiatives, potentially transforming childbirth safety and further reducing maternal mortality ratio across the country.